Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Assets Average (2018 - 2025)

VYNE Therapeutics (VYNE) has disclosed Assets Average for 8 consecutive years, with $37.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average fell 47.68% year-over-year to $37.4 million, compared with a TTM value of $37.4 million through Dec 2025, down 47.68%, and an annual FY2025 reading of $48.5 million, down 41.03% over the prior year.
  • Assets Average was $37.4 million for Q4 2025 at VYNE Therapeutics, down from $50.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $141.6 million in Q2 2021 and bottomed at $22.1 million in Q3 2023.
  • Average Assets Average over 5 years is $70.9 million, with a median of $65.7 million recorded in 2022.
  • The sharpest move saw Assets Average plummeted 57.79% in 2022, then surged 268.21% in 2024.
  • Year by year, Assets Average stood at $74.2 million in 2021, then fell by 19.45% to $59.8 million in 2022, then fell by 2.14% to $58.5 million in 2023, then rose by 22.36% to $71.6 million in 2024, then crashed by 47.68% to $37.4 million in 2025.
  • Business Quant data shows Assets Average for VYNE at $37.4 million in Q4 2025, $50.6 million in Q2 2025, and $61.7 million in Q1 2025.